Clinical outcome and prognosis of patients with primary sinonasal tract diffuse large B-cell lymphoma treated with rituximab-cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy: a study by the Consortium for Improving Survival of Lymphoma.
- Authors
- Lee, Gyeong-Won; Go, Se-Il; Kim, Seok-Hyun; Hong, Junshik; Kim, Yu Ri; Oh, Sukjoong; Kim, Sung-Yong; Do, Young Rok; Lee, Hyewon; Song, Moo Kon
- Issue Date
- Apr-2015
- Publisher
- INFORMA HEALTHCARE
- Keywords
- Diffuse large cell lymphomas; nasal cavities; paranasal sinus; rituximab
- Citation
- LEUKEMIA & LYMPHOMA, v.56, no.4, pp.1020 - 1026
- Indexed
- SCIE
SCOPUS
- Journal Title
- LEUKEMIA & LYMPHOMA
- Volume
- 56
- Number
- 4
- Start Page
- 1020
- End Page
- 1026
- URI
- https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/157457
- DOI
- 10.3109/10428194.2014.946027
- ISSN
- 1042-8194
- Abstract
- We evaluated the clinical outcomes and relapse patterns of 80 patients with primary sinonasal tract diffuse large B-cell lymphoma(SN-DLBCL)treatedwithrituximab-cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) chemotherapy at 22 institutions. A total of 59 (73.8%) patients received R-CHOP chemotherapy alone, whereas 21(26.3%) were treated with R-CHOP followed by involved field radiotherapy (IFRT). In 73 patients with Ann Arbor stage I-II disease, no significant difference was found in the response rate or overall survival (OS) between R-CHOP alone (n = 52) and R-CHOP followed by IFRT (n = 21). Among 11 relapsed patients in this study, the most common pattern of relapse was local (n = 8, 11.8%), whereas central nervous system (CNS) relapse was observed in only one (1.9%) patient. These results suggest that patients with primary SN-DLBCL treated with R-CHOP have a relatively low CNS relapse rate and better OS compared to previous studies before the introduction of R.
- Files in This Item
-
Go to Link
- Appears in
Collections - 서울 의과대학 > 서울 교육협력지원교실 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/157457)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.